Stock ALM ALMIRALL, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Almirall, S.A.

Equities

ALM

ES0157097017

Pharmaceuticals

Market Closed - BME
Other stock markets
 11:35:26 2024-04-26 am EDT 		5-day change 1st Jan Change
8.57 EUR +1.24% Intraday chart for Almirall, S.A. +4.00% +1.72%
Mar. 13 Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment MT
Feb. 19 Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB... Our Logo

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,555 1,945 2,031 1,641 1,764 1,795 - -
Enterprise Value (EV) 1 2,939 2,338 2,197 1,756 1,732 1,694 1,662 1,552
P/E ratio 24.4 x 24.8 x -49.1 x 452 x -42.1 x 83.3 x 29.9 x 17.6 x
Yield 1.37% 1.74% 1.68% - 2.26% 2.18% 2.2% 2.28%
Capitalization / Revenue 3 x 2.41 x 2.51 x 1.9 x 1.97 x 1.85 x 1.68 x 1.51 x
EV / Revenue 3.44 x 2.9 x 2.71 x 2.03 x 1.94 x 1.74 x 1.55 x 1.3 x
EV / EBITDA 9.66 x 9.81 x 9.33 x 8.85 x 9.95 x 9.13 x 7.28 x 5.6 x
EV / FCF 20.8 x 16.8 x 13.5 x 45.5 x -26.3 x 23.5 x 18.5 x 10.2 x
FCF Yield 4.8% 5.96% 7.41% 2.2% -3.8% 4.25% 5.41% 9.76%
Price to Book 2.02 x 1.49 x 1.57 x - 1.13 x 1.17 x 1.15 x 1.12 x
Nbr of stocks (in thousands) 174,555 178,116 179,777 181,515 209,394 209,394 - -
Reference price 2 14.64 10.92 11.30 9.040 8.425 8.570 8.570 8.570
Announcement Date 2/24/20 2/22/21 2/21/22 2/20/23 2/19/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 853.1 807.4 809.8 863.2 894.5 971.5 1,071 1,190
EBITDA 1 304.2 238.3 235.6 198.3 174.1 185.6 228.4 277.3
EBIT 1 174.8 115.2 115.7 46.87 49.8 54.17 97.46 132.8
Operating Margin 20.49% 14.27% 14.28% 5.43% 5.57% 5.58% 9.1% 11.16%
Earnings before Tax (EBT) 1 128.3 79.24 -9.085 31.03 -17.19 37.86 74.58 122.2
Net income 1 105.9 74.28 -40.86 4.281 -38.47 25.16 62.12 101.7
Net margin 12.41% 9.2% -5.05% 0.5% -4.3% 2.59% 5.8% 8.54%
EPS 2 0.6000 0.4400 -0.2300 0.0200 -0.2000 0.1029 0.2869 0.4874
Free Cash Flow 1 141.1 139.4 162.7 38.6 -65.82 72.1 89.95 151.5
FCF margin 16.53% 17.26% 20.09% 4.47% -7.36% 7.42% 8.4% 12.73%
FCF Conversion (EBITDA) 46.37% 58.5% 69.06% 19.47% - 38.85% 39.39% 54.63%
FCF Conversion (Net income) 133.19% 187.67% - 901.66% - 286.56% 144.79% 149.01%
Dividend per Share 2 0.2000 0.1900 0.1900 - 0.1900 0.1866 0.1890 0.1957
Announcement Date 2/24/20 2/22/21 2/21/22 2/20/23 2/19/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 426 425.9 175.8 208.1 218.8 217.8 436.6 197.2 229.4 232 234.1 466.1 208.5 219.9 235.9 249.6 235.6 243.7
EBITDA 1 137.2 136.6 44.6 54.4 50.3 48 107.6 38.8 51.9 51.8 49.5 101.3 36.9 35.9 44.6 50.8 42.1 45.1
EBIT 1 75.3 77.6 15.1 22.96 30.3 17.9 48.2 7.9 -9.234 20.3 18.58 38.88 5.9 5.4 15 - - -
Operating Margin 17.68% 18.22% 8.59% 11.03% 13.85% 8.22% 11.04% 4.01% -4.02% 8.75% 7.94% 8.34% 2.83% 2.46% 6.36% - - -
Earnings before Tax (EBT) 1 50.42 -26.91 7.8 10.02 28.1 13.7 41.8 -18.5 7.727 7.7 12.72 28.12 8.4 -53.69 7 14.6 5.9 8.9
Net income 1 42.37 -42.85 3.447 -1.459 20.4 6.9 27.3 -16.4 -6.619 7.7 4.315 12.02 1.59 -52.07 2.8 5.9 2.4 3.6
Net margin 9.95% -10.06% 1.96% -0.7% 9.32% 3.17% 6.25% -8.32% -2.88% 3.32% 1.84% 2.58% 0.76% -23.68% 1.19% 2.36% 1.02% 1.48%
EPS 2 0.2500 -0.2400 0.0200 -0.0100 0.1100 0.0400 - -0.0900 -0.0400 - - - - - 0.0100 0.0300 0.0100 0.0200
Dividend per Share - - - - - - - - - - - - - - - - - -
Announcement Date 7/27/20 7/26/21 11/15/21 2/21/22 5/9/22 7/25/22 7/25/22 11/10/22 2/20/23 5/8/23 7/24/23 7/24/23 11/9/23 2/19/24 - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 383 393 166 115 - - - -
Net Cash position 1 - - - - 32.3 100 132 242
Leverage (Debt/EBITDA) 1.259 x 1.647 x 0.7025 x 0.5788 x - - - -
Free Cash Flow 1 141 139 163 38.6 -65.8 72.1 90 151
ROE (net income / shareholders' equity) 11% 5.75% 6.29% 2.57% 1.12% 1.87% 4.36% 6.64%
ROA (Net income/ Total Assets) - - - 1.56% 0.69% 0.83% 2% 3.39%
Assets 1 - - - 274.1 -5,577 3,030 3,102 2,998
Book Value Per Share 2 7.250 7.320 7.190 - 7.430 7.310 7.450 7.660
Cash Flow per Share 2 1.560 0.9800 1.320 0.7200 0.4700 0.5600 0.6500 0.7600
Capex 1 135 25.7 71.2 117 159 82.6 74.5 80.4
Capex / Sales 15.83% 3.18% 8.79% 13.5% 17.81% 8.5% 6.96% 6.75%
Announcement Date 2/24/20 2/22/21 2/21/22 2/20/23 2/19/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Almirall, S.A.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
8.57 EUR
Average target price
11.21 EUR
Spread / Average Target
+30.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ALMIRALL, S.A. Stock Almirall, S.A.
+1.72% 1.92B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ALM Stock
  4. Financials Almirall, S.A.